Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and Vanda (VNDA – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arcutis Biotherapeutics (ARQT)
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $37.00. The company’s shares closed last Wednesday at $27.01.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $34.13 average price target, which is a 26.2% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Vanda (VNDA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda, with a price target of $24.00. The company’s shares closed last Wednesday at $8.28.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vanda with a $14.88 average price target, which is a 75.3% upside from current levels. In a report issued on February 12, Cantor Fitzgerald also maintained a Buy rating on the stock with a $11.00 price target.
